Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial

IMPORTANCE: Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. OBJECTIVE: To examine whether T-VEC in combination with pembrolizumab is ass...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Kelly, Ciara M., Antonescu, Cristina R., Bowler, Timothy, Munhoz, Rodrigo, Chi, Ping, Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Movva, Sujana, Dholakia, Reena, Ahmad, Hamza, Biniakewitz, Matthew, Condy, Mercedes, Phelan, Haley, Callahan, Margaret, Wong, Phillip, Singer, Sam, Ariyan, Charlotte, Bartlett, Edmund K., Crago, Aimee, Yoon, Sam, Hwang, Sinchun, Erinjeri, Joseph P., Qin, Li-Xuan, Tap, William D., D’Angelo, Sandra P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990941/
https://ncbi.nlm.nih.gov/pubmed/31971541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados